The ability of PEG-OB(Cys10, Cys13) treatment to reduce high phospholipid levels in plasma of DIO animals therefore suggests that obestatin may be able to ameliorate lipoprotein/phospholipid mediated proinflammatory stress associated with complications of obesity and/or diabetes. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.